1.
Modified RECIST (mRECIST) assesment for hepatocellular carcinoma.
Lencioni R,
Llovet J.
Semin Liver Dis 2010;30:52-60.
2.
Consensus report of the fifth international forum for liver MRI.
Zech CJ,
Bartolozzi C,
Bioulac-Sage P,
et al.
AJR 2013;201:97-107.
3.
Imaging assesment of hepatocellular carcinoma response to locoregional and systemic therapy.
Yaghmai V,
Besa C,
Kim E,
et al.
AJR 2013;201:80-96.
4.
Local-Regional treatment of hepatocellular carcinoma.
Lencioni R,
Crocetti L.
Radiology 2012; Volume 262,
Number 1,
January: 43-58.
5.
Lack of response after initial chemoembolization for hepatocellular carcinoma: Does it predict failure of subsequent treatment?.
Georgiades C,
Geschwind JF,
Harrison N,
et al.
Radiology 2012; Volume 265,
Number 1,
October: 115-123.
6.
MR imaging of hypervascular lesions in the cirrothic liver: a diagnostic dilemma.
Parente D,
Perez R,
Eiras-Araujo A,
et al.
Radiographics 2012;32:767-787.
7.Imaging - based diagnostic systems for hepatocellular carcinoma.
Cruite I,
Tang A,
Sirlin C.
AJR 2013; 201:41-55.
8.
The road less traveled: importance of the lesser branches of the celiac axis in liver embolotherapy.
Lee A,
Gomes A,
Liu D,
et al.
Radiographics 2012; 32:1121- 1132.
9.
Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead (DEBDOX): Technical recommendations.
Lencioni R,
de Baere T,
Burrel M,
et al.
Cardiovascular Interventional Radiology DOI 10.1007/s00270-011-0287-7